Sol-Gel Technologies Announces FDA Approval of TWYNEO acne med

 

• TWYNEO®, a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide
  
  
• TWYNEO utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038
• Under a previously announced license, Sol-Gel to receive regulatory milestone payment from U.S. commercialization partner, Galderma, in conjunction with this approval and retains the option to regain commercialization rights five years following first commercialization in the U.S.

https://www.globenewswire.com/news-release/2021/07/27/2269561/0/en/Sol-Gel-Technologies-Announces-FDA-Approval-of-TWYNEO.html